Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price Negotiation Purgatory: Upcoming Biosimilars Couldn’t Keep Stelara, NovoLog Off The List

Executive Summary

Neither product counts as an ‘extended monopoly’ drug under the Inflation Reduction Act, meaning biosimilar entry cannot prevent Medicare from negotiating its price.

You may also be interested in...

Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA

The inaugural class of drugs subject to the new US Medicare price negotiation process includes four antidiabetics. But none are from the biggest and fastest growing class – thanks to few technicalities in how the law works.

Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data

Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.

CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program

Statements on patient experience with the diseases treated by the drugs subject to price negotiation and how they impact their lives are requested; 10 meetings are planned for the fall.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts